Equities
Consumer ServicesFood & Drug Retailers
  • Price (USD)78.36
  • Today's Change0.63 / 0.81%
  • Shares traded256.61k
  • 1 Year change-7.56%
  • Beta0.9912
Data delayed at least 15 minutes, as of May 20 2019 15:24 BST.
More ▼

Profile data is unavailable for this security.

About the company

AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company's segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers. Servicing healthcare providers in the pharmaceutical supply channel, the Pharmaceutical Distribution segment's operations provide drug distribution and related services. The Other segment consists of the operations of various segments, including the AmerisourceBergen Consulting Services (ABCS), the World Courier Group, Inc. and the MWI Veterinary Supply, Inc. ABSG operates distribution facilities that focus primarily on complex disease treatment regimens.

  • Revenue in USD (TTM)175.15bn
  • Net income in USD867.88m
  • Incorporated2001
  • Employees21.00k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SAGE Therapeutics Inc90.74m-461.69m8.59bn637.00--6.50--94.68-9.74-9.741.9225.860.0719----142,445.80-36.59-53.66-38.20-58.90-----508.82-1,030.54----0.00-------38.04--294.32--
Sarepta Therapeutics Inc323.44m-403.20m9.02bn499.00--6.69--27.89-5.94-5.944.7618.190.19820.33927.16648,178.40-24.70-31.69-26.56-35.7187.42---124.66-219.4011.15-26.540.24--94.7484.14-614.01--76.33--
Ionis Pharmaceuticals Inc752.47m359.60m9.46bn737.0026.337.7928.6612.572.562.565.458.650.363933.6531.811,020,992.0015.322.1018.602.5255.0127.7542.096.249.369.940.3250.0016.6332.42154.30--54.38--
Mylan NV11.24bn225.90m10.12bn35.00k44.920.8534.720.90030.43730.465321.7923.030.33522.534.57321,282.800.67342.580.7993.1739.8243.622.016.640.85472.640.53610.00-3.9810.60-59.01-11.5324.77--
Seattle Genetics, Inc.709.31m-124.31m10.71bn1.30k--8.15--15.11-0.7873-0.78734.418.150.46271.195.15544,784.20-8.11-16.85-9.24-20.5988.3288.47-17.53-31.442.95--0.00--35.7619.45-77.40---0.8587--
Elanco Animal Health Inc-100.00bn-100.00bn12.08bn5.59k----------------------------------49.85---2.54--------6.159.72125.16-14.65----
EXACT Sciences Corporation526.21m-218.78m12.42bn1.98k--15.98--23.61-1.76-1.764.266.020.34763.6111.61266,165.40-14.45-33.75-15.70-36.9473.7168.50-41.58-97.508.13-6.810.5058--70.86155.8726.81--76.69--
Cardinal Health Inc143.53bn19.00m13.42bn50.20k297.172.1512.990.09350.15150.0999472.5320.913.5111.1218.462,859,163.000.05132.730.11516.294.805.350.01460.76710.54185.780.59358.285.266.24-149.61--14.5112.53
BioMarin Pharmaceutical Inc.1.52bn-89.54m15.89bn2.85k--5.413,207.2310.46-0.5033-0.50338.5516.400.33630.64244.27532,997.60-1.98-5.98-2.31-6.8478.7981.28-5.90-19.562.76--0.2237--13.5222.14-3.30--17.28--
AmerisourceBergen Corp.175.15bn867.88m16.34bn21.00k19.425.5911.850.09334.004.29810.1913.904.5414.0514.328,340,548.002.152.008.468.552.782.730.47370.40630.556211.160.604547.299.6613.81186.9316.2110.6912.59
Incyte Corporation2.00bn252.95m16.55bn1.37k66.007.9353.688.291.171.179.259.730.789513.118.601,461,198.0010.00-1.9111.73-2.3396.1496.4412.66-2.445.217.820.0091--22.5039.60134.97--76.69--
McKesson Corporation214.32bn-53.00m23.75bn78.00k--2.9321.260.1108-0.41060.041,090.6842.603.5712.2711.92--0.27993.150.79168.615.485.750.07840.91350.57829.760.439714.532.869.3093.42--6.0610.66
Data as of May 20 2019. Currency figures normalised to AmerisourceBergen Corp's reporting currency: US Dollar USD

Institutional shareholders

25.65%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 201915.96m7.56%
BlackRock Fund Advisorsas of 31 Mar 20198.10m3.84%
SSgA Funds Management, Inc.as of 31 Mar 20197.23m3.43%
Fidelity Management & Research Co.as of 31 Mar 20195.24m2.48%
JPMorgan Investment Management, Inc.as of 31 Mar 20194.04m1.91%
Templeton Global Advisors Ltd.as of 31 Mar 20193.76m1.78%
Victory Capital Management, Inc.(Investment Management)as of 31 Mar 20192.52m1.20%
Vulcan Value Partners LLCas of 31 Mar 20192.46m1.16%
Northern Trust Investments, Inc.as of 31 Mar 20192.43m1.15%
The Baupost Group LLCas of 31 Mar 20192.40m1.14%
More ▼
Data from 31 Mar 2019 - 31 Mar 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.